At contrast to these studies, a recent study demonstrated an enhanced mRNA expression of PD-1, PD-L1, and PD-L2 in breast cancer patients post CT or post hormonal therapy, which could be associated with a more beneficial OS even in multivariate analysis (Karsono et al. 2021). Here, PDCD1LG2 is linked to breast carcinoma.